Vamanu Emanuel, Gatea Florentina, Sârbu Ionela, Pelinescu Diana
Faculty of Biotechnology, University of Agronomic Science and Veterinary Medicine, 59 Marasti blvd, 1 district, 011464 Bucharest, Romania.
Centre of Bioanalysis, National Institute for Biological Sciences, 296 Spl. Independentei, 060031 Bucharest, Romania.
Pharmaceutics. 2019 Apr 18;11(4):191. doi: 10.3390/pharmaceutics11040191.
The multiple causes of cardiovascular diseases signify a major incidence and developmental risk of this pathology. One of the processes accountable for this pathologic development is the instauration of dysbiosis and its connection with an inflammatory process. Low antioxidant colonic protection encourages the progression of inflammation, with cardiovascular dysfunctions being a secondary consequence of the dysbiosis. Curcumin is one of the bioactive compounds displaying promising results for the reduction of an inflammatory process. The present study aims at demonstrating the capacity of three extracts drawn from () through an in vitro simulation process, for microbiota modulation in patients with hypertension. The acidic pH in the extraction process determined a high curcumin content in the extracts. The major phenolic compound identified was curcumin III, 622 ± 6.88 µg/mL for the ethanol/water/acetic acid extract. Low EC50 values were associated (0.2 µg/mL for DPPH scavenging activity) with the presence of curcumin isomers. A metabolic pattern became evident because the relationship between the short-chain fatty acids acted as a clinical biomarker. The curcumin present stimulated the formation of butyric and propionic acids. Microbiota activity control included a high degree of curcumin degradation and biotransformation in the other phenolic compounds. This developmental process was supported by the progression in the enterobacteria with a corresponding escalation in the pH level. The metabolomic pattern demonstrated a performance similar to the administration of dietary fibre, with the positive effects being dose-dependent.
心血管疾病的多种病因表明了这种病理状况的主要发病率和发展风险。导致这种病理发展的过程之一是肠道菌群失调的形成及其与炎症过程的关联。结肠抗氧化保护能力低会促使炎症进展，心血管功能障碍是菌群失调的次要后果。姜黄素是一种生物活性化合物，在减轻炎症过程方面显示出有前景的结果。本研究旨在通过体外模拟过程证明从（）中提取的三种提取物对高血压患者肠道菌群调节的能力。提取过程中的酸性pH值决定了提取物中姜黄素含量高。鉴定出的主要酚类化合物是姜黄素III，乙醇/水/乙酸提取物中的含量为622±6.88μg/mL。低EC50值（DPPH清除活性为0.2μg/mL）与姜黄素异构体的存在有关。由于短链脂肪酸之间的关系作为临床生物标志物，一种代谢模式变得明显。存在的姜黄素刺激了丁酸和丙酸的形成。肠道菌群活性控制包括姜黄素在其他酚类化合物中的高度降解和生物转化。这一发展过程得到了肠杆菌进展以及相应pH值升高的支持。代谢组学模式显示出与膳食纤维给药相似的性能，其积极作用具有剂量依赖性。
